Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.

  title={Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.},
  author={Yoshiko Miyazaki and Tomohiko Harada and Tomohide Akase and Ichiro Arakawa and Tadao Inoue},
  journal={Clinical therapeutics},
  volume={31 Pt 2},
  • Yoshiko Miyazaki, Tomohiko Harada, +2 authors Tadao Inoue
  • Published in Clinical therapeutics 2009
  • Medicine
  • BACKGROUND Randomized, controlled trials (RCTs) in 220 patients with advanced colorectal cancer reported no significant differences in survival periods between folinic acid/5-fluorouracil/irinotecan (FOLFIRI) and folinic acid/5-fluorouracil/oxaliplatin (FOLFOX6) therapies, irrespective of the treatment sequence. Based on a literature search, an economic assessment of both treatments given in 1 of 2 sequences (FOLFIRI and FOLFOX6, or FOLFOX6 and FOLFIRI) has not been conducted in Japan… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv


    Publications referenced by this paper.


    • OECD Health Dat
    • Statistics and Indicators for 30 Countries [CD-ROM]. Paris, France: OECD Publishing;
    • 2008

    C ancer Statistics in Japan 2008 . C ancer incidence by age group , site distribution ( 2002 ) Patients survey for 2005 [ in Japanese ]

    • S Selvin
    • Survival Analysis for Epidemiologic and Medical Research ( Practical Guides to Biostatistics and Epidemiology )
    • 2008

    Allowance for Differential Timing of C osts ( Discounting and the Annuitization of C apital Expenditures )

    • MJ Sculpher, GW Torrance
    • Methods for the Economic Evaluation of Health Care Programmes
    • 2005

    Phase lll randomized trial of FOLFIRl versus FOLFOX 4 in the treatment of advanced colorectal cancer : A multicenter study of the Gruppo Oncologico Dell ’ Italia Meridionale

    • G olucci, V Gebbia, G Paoletti
    • J Clin Oncol
    • 2005

    FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

    Representing Both First- and Second-order Uncertainties by Monte Carlo Simulation for Groups of Patients

    Uncertainty in Decision Models Analyzing Cost-Effectiveness